; QLT Inc. Company Profile - Aug 10, 2011
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

QLT Inc. Company Profile - Aug 10, 2011

VIEWS: 12 PAGES: 13

QLT Inc. (QLT) is a biotechnology company. The Company is engaged in the development and commercialization of therapies for the eye. As of December 31, 2010, QLT was focused on its commercial product, Visudyne, for the treatment of wet age related macular degeneration (wet AMD), and developing its ophthalmic product candidates. Visudyne utilizes light-activated photodynamic therapy (PDT) to treat the eye disease. Visudyne is also used for the treatment of subfoveal choroidal neovascularization (CNV) secondary to pathologic myopia, or severe near-sightedness, and presumed ocular histoplasmosis. As of December 31, 2010, the Company was conducting a Phase Ib clinical proof-of-concept study of QLT091001, which is a synthetic retinoid replacement therapy. The Company is developing QLT091001, which is a synthetic retinoid replacement therapy for 11-cis-retinal, a biochemical component of the retinoid-rhodopsin cycle and visual function.

More Info
  • pg 1
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   QLT Inc.
                                                                                         440 Wheelers Farms Road
                                                                                         Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in Canadian Dollars

                                 Wright Quality Rating:DANN                                Key Data

   QLT Inc. (QLT) is a biotechnology company. The Company is engaged in the                Ticker:
   development and commercialization of therapies for the eye. As of December 31,          QLT
   2010, QLT was focused on its commercial product, Visudyne, for the treatment of
   wet age related macular degeneration (wet AMD), and developing its ophthalmic           2010 Sales:
   product candidates. Visudyne utilizes light-activated photodynamic therapy (PDT) to
                                                                                           46,285,084
   treat the eye disease. Visudyne is also used for the treatment of subfoveal choroidal
   neovascularization (CNV) secondary to pathologic myopia, or severe near-
   sightedness, and presumed ocular histoplasmosis. As of December 31, 2010, the           Major Industry:
   Company was conducting a Phase Ib clinical proof-of-concept study of QLT091001,         Drugs, Cosmetics & Health
   which is a synthetic retinoid replacement therapy. The Company is developing            Care
   QLT091001, which is a synthetic retinoid replacement therapy for 11-cis-retinal, a
   biochemical component of the retinoid-rhodopsin cycle and visual function.              Sub Industry:
                       Stock Chart                                    Officers             Ethical Drug Manufacturers
                                                                     Chairman
                                                                   C. Boyd Clarke          Country:
                                                                                           Canada
                                                         President & Chief Executive
                                                             Robert L. Butchofsky          Currency:
                                                                                           Canadian Dollars
                                                              Vice President Finance &
                                                               Chief Financial Officer
                                                                                           Fiscal Year Ends:
                                                                  Cameron R. Nelson
                                                                                           December

                                                                                           Employees
                                                                                           172

                        
								
To top